Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Fluzone Quadrivalent and High-Dose (2017-2018)
NCT03308825Phase 4Completed
- Sponsor
- Sanofi
- Start
- Sep 2017
- Primary completion
- Nov 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated) and trivalent inactivated influenza vaccine high-dose in influenza (4 arms), sponsored by Sanofi. Primary endpoints: Number of Participants Reporting Solicited Injection Site and Systemic Reactions at 7 days, Geometric Mean Titers of Influenza Vaccine Antibodies at Day 28 and 3 more. Started Sep 2017; status: completed.
02
Drugs
Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated)trivalent inactivated influenza vaccine high-dose
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03308825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03308825.